iX Biopharma Ltd. (SG:42C) has released an update.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
iX Biopharma is escalating its efforts to out-license Wafermine, its non-opioid pain treatment with potential applications in Complex Regional Pain Syndrome and depressive disorders, by partnering with the global life sciences advisory firm Kybora. The company is setting its sights on global markets, banking on Wafermine’s US FDA Orphan Drug Designation, which promises 7 years of market exclusivity and development incentives. With a focus on safety and effectiveness, Wafermine represents a promising alternative to opioid painkillers and a potential breakthrough for treatment-resistant depression.
For further insights into SG:42C stock, check out TipRanks’ Stock Analysis page.